Skip to main
EQ

Equillium Inc (EQ) Stock Forecast & Price Target

Equillium Inc (EQ) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Equillium is a biotechnology company with a promising lead drug candidate, EQ504, for the treatment of severe autoimmune and inflammatory disorders such as UC and Celiac Disease. The company has a strong pipeline with potential catalysts in the near future, which could positively impact its value. The author maintains a positive outlook on Equillium, citing a differentiated safety profile and potential for widespread use of EQ504 in the treatment of UC.

Bears say

Equillium is a high-risk investment due to the uncertainties surrounding the effectiveness and safety of its lead drug, EQ504. While the drug has shown promise in early trials and has a buy rating, there are concerns about its potential in human subjects. With a projected peak sales of $3.15B, Equillium faces potential risks as a clinical-stage biotechnology company and further research is needed to validate the efficacy of its drug in treating severe autoimmune and inflammatory disorders.

Equillium Inc (EQ) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Equillium Inc (EQ) Forecast

Analysts have given Equillium Inc (EQ) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Equillium Inc (EQ) has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Equillium Inc (EQ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.